Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Xeris Biopharma Holdings (XERS) over the last 4 years, with Dec 2024 value amounting to -$0.37.

  • Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) rose 103.18% to $0.00 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.10, marking a year-over-year increase of 78.07%. This contributed to the annual value of -$0.37 for FY2024, which is 17.78% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.37 for FY2024, which was up 17.78% from -$0.45 recorded in FY2023.
  • Xeris Biopharma Holdings' 5-year EPS (Weighted Average and Diluted) high stood at -$0.37 for FY2024, and its period low was -$1.55 during FY2021.
  • In the last 3 years, Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) had a median value of -$0.45 in 2023 and averaged -$0.51.
  • Data for Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) shows a peak YoY spiked of 54.84% (in 2022) over the last 5 years.
  • Over the past 4 years, Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) (Yearly) stood at -$1.55 in 2021, then spiked by 54.84% to -$0.70 in 2022, then surged by 35.71% to -$0.45 in 2023, then grew by 17.78% to -$0.37 in 2024.